(Q37825945)

23 August 2017

1 reference

title

Therapies for diabetic dyslipidaemia (English)

1 reference

23 August 2017

1 reference

D S H Bell

1

1 reference

23 August 2017

F Al Badarin

series ordinal

2

1 reference

23 August 2017

J H O'Keefe

series ordinal

3

1 reference

23 August 2017

publication date

1 April 2011

1 reference

Diabetes, Obesity and Metabolism

23 August 2017

published in

1 reference

23 August 2017

volume

13

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

313-325

1 reference

Approach to lipoprotein management in 2001 National Cholesterol Guidelines

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

The role of oxidative stress in diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Role of triglycerides in coronary artery disease: lessons from the Prospective Cardiovascular Münster Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

The pattern of dyslipidemia among urban African-Americans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Mechanism of intestinal lipoprotein overproduction in insulin resistant humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Prevalence and determinants of glucose intolerance in a Dutch caucasian population. The Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Diabetes, the metabolic syndrome, and angiographic progression of coronary arterial disease in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Effect of nateglinide on the incidence of diabetes and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Standards of medical care in diabetes--2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Achieving hunter-gatherer fitness in the 21(st) century: back to the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Mediterranean-style dietary pattern, reduced risk of metabolic syndrome traits, and incidence in the Framingham Offspring Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Anatomy of health effects of Mediterranean diet: Greek EPIC prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Testosterone concentrations in diabetic and nondiabetic obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Cardiovascular issues in hypogonadism and testosterone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Endogenous sex hormones and metabolic syndrome in aging men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Adverse events associated with testosterone administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Testosterone deficiency and replacement in older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Effect of temocapril hydrochloride on serum lipid levels in patients with hypertensive type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Rediscovering bile acid sequestrants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Statin therapy and risk of developing type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Statins and biomarkers of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Statin use is associated with enhanced collateralization of severely diseased coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Should C-reactive protein be measured routinely during acute myocardial infarction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Elevated lipoprotein (a) and apolipoprotein B to AI ratio in South Asian patients with ischaemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

ACCORD and Risk-Factor Control in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Effects of a small quantity of omega-3 fatty acids on cardiovascular risk factors in NIDDM. A randomized, prospective, double-blind, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Autonomic function, omega-3, and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Ezetimibe: cholesterol lowering and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01342.X

10.1111/J.1463-1326.2010.01342.X

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference